Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025

The non-radiographic axial spondyloarthritis therapeutics market size has grown rapidly in recent years. It will grow from $0.93 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period is due to various factors such as an increase in the prevalence of axial spondyloarthritis, rising disease awareness, a growing patient population, expanding adoption of biologic therapies, and heightened research and development efforts.

The non-radiographic axial spondyloarthritis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during the forecast period can be linked to the rising awareness and early detection of the condition, proliferation of biosimilars, continuous improvements in biologic drugs and upcoming treatment innovations, increasing focus on R&D, a higher uptake of targeted and personalized treatment strategies, and advancements in healthcare infrastructure. Prominent trends expected during this period include development of personalized therapeutic approaches, use of digital tools for diagnosis, a growing preference for treat-to-target strategies, implementation of value-based pricing frameworks, and broader adoption of multidisciplinary management models.

The increasing number of clinical trials is expected to propel the growth of the non-radiographic axial spondyloarthritis therapeutic market. Clinical trials, which are research studies conducted on humans, are essential for evaluating the safety, effectiveness, and side effects of medical treatments or interventions. The rise in clinical trials is largely driven by the growing demand for personalized and innovative treatments that require rigorous testing to ensure safety and efficacy. These trials provide evidence-based validation of treatment effectiveness and safety in early-stage disease, which is critical for guiding regulatory approvals and clinical adoption of non-radiographic axial spondyloarthritis therapeutics. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a 15% increase in annual recruitment to industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. This trend indicates that the growing number of clinical trials is significantly contributing to market expansion.

Companies operating in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are increasingly focusing on securing regulatory approvals to broaden their market presence, reduce time-to-market for new therapies, and gain a competitive edge. Regulatory approvals involve official authorization from government agencies, allowing drugs or therapies to be legally marketed and prescribed once their safety, efficacy, and compliance with standards have been verified. For instance, in October 2022, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for Rinvoq (upadacitinib) to treat adults with active non-radiographic axial spondyloarthritis who have objective signs of inflammation and have not responded adequately to TNF inhibitors. This approval marks the sixth U.S. indication for Rinvoq and makes it the first and only oral JAK inhibitor approved for nr-axSpA. The decision was based on results from the SELECT-AXIS 2 clinical trial, which showed that nearly half of the patients treated with Rinvoq experienced significant improvements in disease activity at 14 weeks compared to those receiving a placebo. This approval offers a new once-daily oral treatment option for patients facing this challenging condition.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics for an undisclosed sum. The acquisition aims to bolster Eli Lilly’s immunology portfolio by integrating DICE’s promising oral IL-17 inhibitors for autoimmune diseases. This move enhances Eli Lilly's capacity to address chronic inflammatory conditions with innovative and patient-friendly oral therapies. DICE Therapeutics, a US-based biopharmaceutical company, is known for its oral IL-17 antagonists, including DC-806 and DC-853, developed for treating non-radiographic axial spondyloarthritis and other autoimmune diseases.

Major players in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., and Qyuns Therapeutics Co. Ltd.

North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in non-radiographic axial spondyloarthritis therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-radiographic axial spondyloarthritis therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Non-radiographic axial spondyloarthritis therapeutics refer to treatments designed to manage symptoms and slow disease progression in individuals who do not exhibit visible joint damage on X-rays. These therapies primarily include non-steroidal anti-inflammatory drugs (NSAIDs), biologic treatments such as TNF and IL-17 inhibitors, and JAK inhibitors. The primary objectives are to alleviate inflammation, enhance physical function, and prevent the emergence of radiographic changes in the spine and joints.

The key categories of non-radiographic axial spondyloarthritis therapies include non-steroidal anti-inflammatory drugs, biologics, small molecule treatments, and corticosteroids. NSAIDs help reduce inflammation, pain, and fever by blocking enzymes involved in the production of prostaglandins. These drugs can be administered through oral, injectable, and topical methods and are utilized across various settings, including hospitals, ambulatory surgical centers, and homecare environments.

The non-radiographic axial spondyloarthritis therapeutic market research report is one of a series of new reports that provides non-radiographic axial spondyloarthritis therapeutic market statistics, including non-radiographic axial spondyloarthritis therapeutic industry global market size, regional shares, competitors with a non-radiographic axial spondyloarthritis therapeutic market share, detailed non-radiographic axial spondyloarthritis therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the non-radiographic axial spondyloarthritis therapeutic industry. This non-radiographic axial spondyloarthritis therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-radiographic axial spondyloarthritis therapeutic market consists of sales of TNF inhibitors, JAK inhibitors, non-steroidal anti-inflammatory drugs, and IL-23 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.